>>Signaling Pathways>> Apoptosis>> RIP kinase>>RIPK1-IN-7

RIPK1-IN-7

Catalog No.GC37536

RIPK1-IN-7은 Kd가 4nM이고 효소 IC50이 11nM인 강력하고 선택적인 RIPK1 억제제입니다. RIPK1-IN-7은 실험적 B16 흑색종 폐 전이 모델에서 우수한 전이 방지 활성을 나타냅니다.

Products are for research use only. Not for human use. We do not sell to patients.

RIPK1-IN-7 Chemical Structure

Cas No.: 2300982-44-7

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$337.00
재고 있음
5mg
US$306.00
재고 있음
10mg
US$490.00
재고 있음
50mg
US$1,530.00
재고 있음
100mg
US$2,244.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model[1]. IC50: 11 nM (RIPK1)[1]Kd: 4 nM (RIPK1)[1]

RIPK1-IN-7 shows potent cell protection effect in the TSZ-induced HT29 cell necroptosis model with an EC50 of 2nM[1].RIPK1-IN-7 displays considerable activity against several other kinases, such as Flt4, TrkA, TrkB, TrkC, Axl, HRI, Mer, and MAP4K5 with IC50s of 20, 26, 8, 7, 35, 26, 29, and 27 nM, respectively[1].

[1]. Li Y, et al. Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model. J Med Chem. 2018 Dec 27;61(24):11398-11414.

리뷰

Review for RIPK1-IN-7

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for RIPK1-IN-7

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.